Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Efficacy And Safety Of Kcentra Versus Feiba In Patients With Intracerebral Hemorrhage Secondary To Oral Anticoagulants
Cerebrovascular Disease and Interventional Neurology
Cerebrovascular Disease and Interventional Neurology Posters (7:00 AM-5:00 PM)
081
To compare the effect of Kcentra with FEIBA on outcome in patients with intracerebral hemorrhage who were taking oral anticoagulants.
Several pharmacological agents are now available for rapid reversal of oral anticoagulants in patients with major and life-threatening hemorrhages. We compared Kcentra based on inactivated vitamin K dependent factors with factor eight inhibitor bypassing agent (FEIBA) based on activated factors for urgent anticoagulant reversal in patients with intracerebral hemorrhage
We analyzed data from Cerner Health Facts® which collected data from participating facilities from January 1, 2000 to July 1, 2018. We identified patients with intracerebral hemorrhage who received Kcentra or FEIBA for oral anticoagulant reversal. Outcome was defined by discharge destination and was classified into none to minimal disability, moderate to severe disability, or death. 
A total of 10 (10.8%) and 82 of 92 patients with intracerebral hemorrhage taking oral anticoagulants received FEIBA or Kcentra, respectively. There was no difference in rates of intraventricular catheter placement (10% versus 1.2%), intubation/mechanical ventilation (30% versus 18.3%) or hydrocephalus (20% versus 2.4%) between patients who received FEIBA compared with those who received Kcentra. There was also no difference in in- hospital mortality rates (40% versus 25.6%) and none to minimal disability (20% versus 13.4%) between patients who received FEIBA and those who received Kcentra. 
We did not find any differences in intracerebral hemorrhage patients who received FEIBA when compared with those who received Kcentra
Authors/Disclosures
Muhammad F. Ishfaq, MD
PRESENTER 		Dr. Ishfaq has nothing to disclose.
Sachin M. Bhagavan, MD Dr. Bhagavan has nothing to disclose.
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
Brandi R. French, MD (University of Missouri) Dr. French has nothing to disclose.
Farhan Siddiq, MD Dr. Siddiq has nothing to disclose.
Camilo R. Gomez, MD, FÂ鶹´«Ã½Ó³»­ (University of Missouri) Dr. Gomez has nothing to disclose.
Hamza I. Maqsood, MD (Dept of Neurology) Dr. Qureshi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for AstraZeneca.